1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsClinical and Translational Science Award (UM1 Clinical Trial Optional) is sponsored by NIH National Center for Advancing Translational Sciences (NCATS). Supports institutions to develop and enhance clinical and translational research programs, fostering collaboration and innovation in biomedical research.
Get alerted about grants like this
Get emailed when new opportunities from “NIH National Center for Advancing Translational Sciences (NCATS)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
CTSA Program Applicant Information | National Center for Advancing Translational Sciences U.S. Department of Health & Human Services National Institutes of Health We provide critical resources and support needed to strengthen the entire spectrum of our nation’s clinical and translational research enterprise.
View the CTSA Program-Funded Activities and Other Sources (PDF - 179KB) The Clinical and Translational Science Awards (CTSA) Program is a national, collaborative consortium focused on bringing more treatments to more patients more quickly through advancing clinical and translational science.
It is designed to develop and implement innovative solutions that will improve the efficiency, quality, and impact of the process for turning observations in the laboratory, clinic, and community into interventions that improve the health of individuals and communities.
Clinical and Translational Science Awards Suite Resources to assist applicants in applying for the Clinical and Translational Science Awards: Clinical and Translational Science Award (UM1 Clinical Trial Optional) Current Notice of Funding Opportunity: PAR-24-272 Application Information and FAQs : Common questions and answers from applicants Overview Diagram of the Application Elements (PDF - 75KB): Provides a visual representation of notice of funding opportunity announcement CTSA Program UM1 Budget Request Tables : Information to assist applicants in determining the allowable amount of a budget request CTSA Program Summary Data Guide and Templates : Blanks and example templates and Other Attachments that must be included with the application submission Research Training and Career Development Awards K12 Current Notice of Funding Opportunity: PAR-25-196 R25 Current Notice of Funding Opportunity: PAR-25-197 T32 predoctoral Current Notice of Funding Opportunity: PAR-25-194 T32 postdoctoral Current Notice of Funding Opportunity: PAR-25-195 Application Information and FAQs for CTSA Program Research Training and Career Development Awards : Common questions and answers from applicants R03 Small Grant Program for the CTSA Program Current Notice of Funding Opportunity: PAR-25-155 RC2 Specialized Innovation Award Current Notice of Funding Opportunity: PAR-25-156 Application Information and FAQs : Common questions and answers from applicants Collaborative Innovation Awards Current Notice of Funding Opportunity: PAR-25-296 Application Information and FAQs for CTSA Program Collaborative and Innovation Acceleration Awards : Common questions and answers from applicants More Information: Collaborating on, Implementing and Disseminating Innovations in Clinical and Translational Science Research CTSA supported conference grants must comply with NCATS-specific Conference Grant Information .
Gallya Gannot, D. M. D, Ph.
D. --> Submission of Prior Approval Requests CTSA Program-Specific Guidelines for Grantees Last updated on March 6, 2026
According to the current listing, eligibility includes: Academic institutions, including universities and medical schools. Confirm the full requirements in the official notice before applying.
Clinical and Translational Science Award (UM1 Clinical Trial Optional) is funded by NIH National Center for Advancing Translational Sciences (NCATS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article